With expertise in research, fundraising, policy and more, our staff are dedicated to making breakthroughs possible. Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

There are two main types of Alzheimer’s. Late onset Alzheimer’s starts after age 65, and young onset Alzheimer’s affects people before age 65. Different genes can be involved in the development of the ...

Dementia with Lewy bodies is the third most common disease that causes dementia. Both risk genes and faulty genes can be involved in dementia with Lewy bodies. Dementia with Lewy bodies (DLB) is ...

Gavin Patterson joins Alzheimer's Research UK as chair. The former President and Chief Revenue Officer of Salesforce and CEO ...

Are you a dementia researcher or professional in the field? Don’t miss out on important updates about our upcoming dementia research events. Our 2026 Research Conference, will take place in Manchester ...

Research has found that people who led an active lifestyle, especially before 50 years old, had better brain health aged 70.

Looking for a challenge to test yourself, to get in shape, or bond with friends on a weekend adventure? If so, an Ultra Challenge® is for you – and you don’t need to be a budding elite athlete – ...

Take on the Cotswold Way Challenge at your own pace – walk, jog, or run a distance that suits you along a marked route. Along the way, you'll enjoy regular rest stops offering free food, drink, and ...

For the majority of people, genes are only one of many factors that may increase their risk of getting dementia. Other factors that affect our dementia risk include our age, lifestyle and environment.

Alzheimer’s Research UK has a large number of different grant schemes through which you can apply for funding. All applications must fall within Alzheimer’s Research UK’s remit which covers biomedical ...